JP2016533373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533373A5 JP2016533373A5 JP2016524100A JP2016524100A JP2016533373A5 JP 2016533373 A5 JP2016533373 A5 JP 2016533373A5 JP 2016524100 A JP2016524100 A JP 2016524100A JP 2016524100 A JP2016524100 A JP 2016524100A JP 2016533373 A5 JP2016533373 A5 JP 2016533373A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tumor
- pancreatic cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *[C@]1O[C@@](*)CN(Cc2ccc(C=C[C@@]3NNc4c3ccc([C@](C3)[C@]3(c3cc(*)ccc3N3*=I)C3=O)c4)cc2)C1 Chemical compound *[C@]1O[C@@](*)CN(Cc2ccc(C=C[C@@]3NNc4c3ccc([C@](C3)[C@]3(c3cc(*)ccc3N3*=I)C3=O)c4)cc2)C1 0.000 description 5
- JOCNOQUWDPPPRY-LYWAIKEGSA-N C[C@H]1O[C@@H](C)CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@H](C5)[C@]5(c5ccccc5N5)C5=O)ccc34)cc2)C1 Chemical compound C[C@H]1O[C@@H](C)CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@H](C5)[C@]5(c5ccccc5N5)C5=O)ccc34)cc2)C1 JOCNOQUWDPPPRY-LYWAIKEGSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892887P | 2013-10-18 | 2013-10-18 | |
| US61/892,887 | 2013-10-18 | ||
| PCT/CA2014/050952 WO2015054781A1 (en) | 2013-10-18 | 2014-10-03 | Treatment for pancreatic cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533373A JP2016533373A (ja) | 2016-10-27 |
| JP2016533373A5 true JP2016533373A5 (enExample) | 2017-11-09 |
| JP6525983B2 JP6525983B2 (ja) | 2019-06-05 |
Family
ID=52827497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524100A Expired - Fee Related JP6525983B2 (ja) | 2013-10-18 | 2014-10-03 | 膵癌の治療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9642856B2 (enExample) |
| EP (1) | EP3057593B1 (enExample) |
| JP (1) | JP6525983B2 (enExample) |
| KR (1) | KR102195494B1 (enExample) |
| CN (1) | CN105764515B (enExample) |
| AU (1) | AU2014336917B2 (enExample) |
| CA (1) | CA2927612C (enExample) |
| EA (1) | EA030089B1 (enExample) |
| ES (1) | ES2908200T3 (enExample) |
| IL (1) | IL245037B (enExample) |
| MX (1) | MX357763B (enExample) |
| SG (1) | SG11201602882VA (enExample) |
| WO (1) | WO2015054781A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8481525B2 (en) | 2009-04-06 | 2013-07-09 | University Of Health Network | Kinase inhibitors and method of treating cancer with same |
| EA023173B1 (ru) | 2010-04-06 | 2016-04-29 | Юниверсити Хелс Нетворк | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью |
| KR20160070106A (ko) | 2013-10-18 | 2016-06-17 | 유니버시티 헬스 네트워크 | Plk-4 억제제의 염 및 결정체들 |
| AU2018328773B2 (en) | 2017-09-08 | 2023-11-16 | University Health Network | Combination therapies for inhibition of Polo-like Kinase 4 |
| SG11202111003UA (en) | 2019-04-24 | 2021-11-29 | Univ Health Network | Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate |
| CN117794529B (zh) | 2021-05-11 | 2025-02-11 | 欧瑞克制药公司 | Polo样激酶4抑制剂 |
| CN115677682B (zh) * | 2021-07-30 | 2023-07-18 | 上海齐鲁制药研究中心有限公司 | 螺环类plk4抑制剂及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US5182397A (en) | 1990-05-31 | 1993-01-26 | American Cyanamid Company | Aryloxyspiroalkylindolinone herbicides |
| GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| AU4155697A (en) | 1996-08-23 | 1998-03-06 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| AU5468499A (en) | 1998-08-04 | 2000-02-28 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
| AU3770000A (en) | 1999-03-24 | 2000-10-09 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| CA2410509A1 (en) | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| US7148249B2 (en) | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
| WO2004037247A1 (en) | 2002-10-21 | 2004-05-06 | Irm Llc | Oxindoles with anti-hiv activity |
| WO2005058309A1 (en) | 2003-12-16 | 2005-06-30 | Leo Pharma A/S | Novel therapeutic use of indolinone derivatives |
| US7309787B2 (en) | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| US20070135509A1 (en) | 2005-12-09 | 2007-06-14 | Blackburn Thomas P | Indolone compounds useful to treat cognitive impairment |
| EP2036894A4 (en) * | 2006-06-30 | 2011-01-12 | Kyowa Hakko Kirin Co Ltd | AURORA INHIBITOR |
| JP5551066B2 (ja) | 2007-06-12 | 2014-07-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| JP2009173629A (ja) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| JP2011506494A (ja) | 2007-12-21 | 2011-03-03 | ユニバーシティ・ヘルス・ネットワーク | 癌の治療に有用なキナーゼ阻害剤としてのインダゾリル、ベンズイミダゾリル、ベンゾトリアゾリル置換インドルモン誘導体 |
| CA2717904C (en) | 2008-03-11 | 2016-08-30 | University Health Network | Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| DE102008040187A1 (de) | 2008-07-04 | 2010-01-07 | Robert Bosch Gmbh | Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung |
| US8481525B2 (en) * | 2009-04-06 | 2013-07-09 | University Of Health Network | Kinase inhibitors and method of treating cancer with same |
| WO2011069298A1 (en) | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
| JP5056876B2 (ja) | 2010-03-19 | 2012-10-24 | Ｊｆｅスチール株式会社 | 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法 |
| EA023173B1 (ru) | 2010-04-06 | 2016-04-29 | Юниверсити Хелс Нетворк | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью |
| US8933070B2 (en) | 2010-07-02 | 2015-01-13 | University Health Network | Methods of targeting PTEN mutant diseases and compositions therefor |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2019006156A1 (en) | 2017-06-29 | 2019-01-03 | Quanticision Diagnostics Inc. | APPARATUS AND METHOD FOR ABSOLUTE QUANTIFICATION OF BIOMARKERS FOR SOLID TUMOR DIAGNOSIS |
-
2014
- 2014-10-03 EP EP14853347.4A patent/EP3057593B1/en active Active
- 2014-10-03 WO PCT/CA2014/050952 patent/WO2015054781A1/en not_active Ceased
- 2014-10-03 MX MX2016004967A patent/MX357763B/es active IP Right Grant
- 2014-10-03 KR KR1020167012617A patent/KR102195494B1/ko not_active Expired - Fee Related
- 2014-10-03 ES ES14853347T patent/ES2908200T3/es active Active
- 2014-10-03 SG SG11201602882VA patent/SG11201602882VA/en unknown
- 2014-10-03 CA CA2927612A patent/CA2927612C/en active Active
- 2014-10-03 CN CN201480064033.0A patent/CN105764515B/zh not_active Expired - Fee Related
- 2014-10-03 EA EA201690763A patent/EA030089B1/ru not_active IP Right Cessation
- 2014-10-03 JP JP2016524100A patent/JP6525983B2/ja not_active Expired - Fee Related
- 2014-10-03 AU AU2014336917A patent/AU2014336917B2/en not_active Ceased
- 2014-10-03 US US15/029,269 patent/US9642856B2/en not_active Expired - Fee Related
-
2016
- 2016-04-11 IL IL245037A patent/IL245037B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533373A5 (enExample) | ||
| Catalano et al. | Gastric cancer | |
| JP2016538344A5 (enExample) | ||
| JP2019523214A5 (enExample) | ||
| JP2015513919A5 (enExample) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2016515561A5 (enExample) | ||
| JP2013503174A5 (enExample) | ||
| JP2017517520A5 (enExample) | ||
| AR094849A1 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer | |
| JP2016501221A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2016506413A5 (enExample) | ||
| JP2017527582A5 (enExample) | ||
| JP2016529285A5 (enExample) | ||
| JP2018513155A5 (enExample) | ||
| JP2019506392A5 (enExample) | ||
| JP2016520057A5 (enExample) | ||
| JP2017516827A5 (enExample) | ||
| JP2013528215A5 (enExample) | ||
| JP2019517507A5 (enExample) | ||
| JP2016529236A5 (enExample) | ||
| Shih et al. | Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models | |
| JP2016540726A5 (enExample) | ||
| JP2020500907A5 (enExample) |